<DOC>
	<DOCNO>NCT00845910</DOCNO>
	<brief_summary>This single arm study evaluate correlation circulate endothelial cell level treatment efficacy patient locally recurrent metastatic breast cancer give first line treatment Avastin combination docetaxel + Xeloda.Patients treat docetaxel 60mg/m2 iv day 1 , Xeloda 900mg/m2 po day 1-14 , 3 week cycle , plus Avastin 7.5 mg/kg iv day 1 3 week cycle . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Circulating Endothelial Cell Marker Avastin ( Bevacizumab ) Combination With Docetaxel Plus Xeloda ( Capecitabine ) First Line Treatment Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>female patient , 1865 year age ; locally recurrent metastatic breast cancer ; measurable evaluable disease ; ECOG performance status 02 ; LVEF &gt; =50 % without clinical symptom sign heart failure . unknown HER2 status , know HER2positive status ; prior chemotherapy locally recurrent metastatic disease ; prior adjuvant neoadjuvant taxane therapy within 12 month prior start treatment ; clinical radiological evidence CNS metastases ; clinically significant cardiovascular disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>